Autolus Therapeutics (NASDAQ:AUTL) Trading Up 6.8% – Time to Buy?

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) rose 6.8% during trading on Wednesday . The company traded as high as $3.31 and last traded at $3.31. Approximately 490,371 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 1,461,731 shares. The stock had previously closed at $3.10.

Analyst Ratings Changes

Several research analysts have recently weighed in on AUTL shares. Needham & Company LLC reissued a “buy” rating and set a $9.00 price objective on shares of Autolus Therapeutics in a report on Monday, November 11th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Autolus Therapeutics currently has an average rating of “Buy” and a consensus target price of $10.15.

Autolus Therapeutics Stock Up 5.7 %

The business’s fifty day moving average is $3.74 and its 200-day moving average is $3.92.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the firm posted ($0.26) EPS. As a group, analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Trading of Autolus Therapeutics

Several hedge funds have recently bought and sold shares of AUTL. Price T Rowe Associates Inc. MD raised its stake in shares of Autolus Therapeutics by 82.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after buying an additional 2,487,778 shares during the period. Bayesian Capital Management LP bought a new stake in Autolus Therapeutics during the 1st quarter worth approximately $100,000. B. Riley Wealth Advisors Inc. purchased a new position in Autolus Therapeutics during the first quarter valued at approximately $108,000. Cetera Advisors LLC bought a new position in shares of Autolus Therapeutics in the first quarter worth approximately $839,000. Finally, SG Americas Securities LLC increased its stake in shares of Autolus Therapeutics by 853.2% in the second quarter. SG Americas Securities LLC now owns 189,240 shares of the company’s stock worth $659,000 after purchasing an additional 169,387 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.